ERBB2 and neoplasm: The tissue samples in Case 12 were longitudinally collected, thus we sought to define whether shifts in clonal composition would take place in the progression from the primary tumor to the brain metastases in this HER2-positive breast cancer following anti-HER2 therapy (Table 1).